

Synthesis and Hemostatic Activity of New Amide Derivatives

Lukasz Banach ¹, Lukasz Janczewski ¹, Jakub Kajdanek ², Katarzyna Milowska ², Joanna Kolodziejczyk-Czepas ³, Grzegorz Galita ⁴, Wioletta Rozpedek-Kaminska ⁴, Ewa Kucharska ⁵, Ireneusz Majsterek ⁴ and Beata Kolesinska ^{1,*}

¹ Faculty of Chemistry, Institute of Organic Chemistry, Lodz University of Technology, Zeromskiego 116, 90-924 Lodz, Poland; lukasz.banach@dokt.p.lodz.pl (L.B.); lukasz.janczewski@p.lodz.pl (L.J.)

² Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland; jakub.kajdanek@edu.uni.lodz.pl (J.K.); katarzyna.milowska@biol.uni.lodz.pl (K.M.)

³ Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland; joanna.kolodziejczyk@biol.uni.lodz.pl

⁴ Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, 90-419 Lodz, Poland; grzegorz.galita@umed.lodz.pl (G.G.); wioletta.rozpedek@umed.lodz.pl (W.R.-K.); ireneusz.majsterek@umed.lodz.pl (I.M.)

⁵ Department of Gerontology, Geriatrics and Social Work, Jesuit University Ignatianum in Cracow, Kopernika 26, 31-501 Krakow, Poland; ewa.kucharska@ignatianum.edu.pl

* Correspondence: beata.kolesinska@p.lodz.pl; Tel.: +48-42-631-32-61

Table of contents:

Figures S1–S32: Copies of ¹ H and ¹³ C NMR spectra of compounds 18–25 and 1–8	S2–S17
Figures S33–S40: Graphs of hemolysis in the presence of compounds 1–8	S18–S20
Figures S41–S43: Graphs of prothrombin time, activated partial thromboplastin time, and thrombin time in the presence of compounds 1–8	S21–S22




Figure S1. ^1H NMR of compound **18** (700 MHz, CDCl_3).




Figure S2. ^{13}C NMR of compound **18** (176 MHz, CDCl_3).




Figure S3. ^1H NMR of compound **19** (700 MHz, CDCl_3).




Figure S4. ^{13}C NMR of compound **19** (176 MHz, CDCl_3).




Figure S5. ^1H NMR of compound **20** (700 MHz, CDCl_3).




Figure S6. ^{13}C NMR of compound **20** (176 MHz, CDCl_3).




Figure S7. ^1H NMR of compound **21** (700 MHz, CDCl_3).




Figure S8. ^{13}C NMR of compound **21** (176 MHz, CDCl_3).




Figure S9. ^1H NMR of compound **22** (700 MHz, CDCl_3).




Figure S10. ^{13}C NMR of compound **22** (176 MHz, CDCl_3).




Figure S11. ^1H NMR of compound **23** (700 MHz, CDCl_3).




Figure S12. ^1H NMR of compound **23** (176 MHz, CDCl_3).





Figure S14. ^{13}C NMR of compound **24** (176 MHz, CDCl_3).




Figure S15. ^1H NMR of compound **25** (700 MHz, CDCl_3).




Figure S16. ^{13}C NMR of compound **25** (176 MHz, CDCl_3).




Figure S17. ^1H NMR of compound **1** (700 MHz, D_2O).




Figure S18. ^{13}C NMR of compound **1** (176 MHz, D_2O).




Figure S19. ^1H NMR of compound **5** (700 MHz, D_2O).




Figure S20. ^{13}C NMR of compound **5** (176 MHz, D_2O).




Figure S21. ^1H NMR of compound **2** (700 MHz, D_2O).




Figure S22. ^{13}C NMR of compound **2** (176 MHz, D_2O).




Figure S23. ^1H NMR of compound **3** (700 MHz, D_2O).




Figure S24. ^{13}C NMR of compound **3** (176 MHz, D_2O).




Figure S25. ^1H NMR of compound **4** (700 MHz, D_2O).




Figure S26. ^{13}C NMR of compound **4** (176 MHz, D_2O).




Figure S27. ^1H NMR of compound **6** (700 MHz, D_2O).




Figure S28. ^{13}C NMR of compound **6** (176 MHz, D_2O).




Figure S29. ^1H NMR of compound 7 (700 MHz, D_2O).




Figure S30. ^{13}C NMR of compound **7** (176 MHz, D_2O).




Figure S31. ^1H NMR of compound **8** (700 MHz, D_2O).




Figure S32. ^{13}C NMR of compound **8** (176 MHz, D_2O).




Figure S33. Graph of hemolysis in the presence amide **1**.




Figure S34. Graph of hemolysis in the presence amide **2**.




Figure S35. Graph of hemolysis in the presence of amide **3**.




Figure S36. Graph of hemolysis in the presence of amide 4.




Figure S37. Graph of hemolysis in the presence of amide 5.




Figure S38. Graph of hemolysis in the presence of 6.




Figure S39. Graph of hemolysis in the presence of amide 7.




Figure S40. Graph of hemolysis in the presence of amide 8.




Figure S41. Graph of prothrombin time (PT) in the presence amides **1–8** and tranexamic acid (TA) in three different concentrations [10, 25 and 50 mg/L] and for control sample - plasma without any extra reagents (*p <0.05).




Figure S42. Graph of activated partial thromboplastin time (aPTT) in the presence amides **1–8** and tranexamic acid (TA) in three different concentrations [10, 25 and 50 mg/L] and for control sample - plasma without any extra reagents.




Figure S43. Graph of the thrombin time (TT) in the presence amides **1–8** and tranexamic acid (TA) in three different concentrations [10, 25 and 50 mg/L] and for control sample - plasma without any extra reagents.